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E-mail address: takumah@shinshu-u.ac.jp (T. HayaUterine leiomyosarcoma (LMS) is a highly metastatic smooth muscle neoplasm for which calponin
h1 is suspected to have a biological role as a tumor-suppressor. We earlier reported that LMP2-null
mice spontaneously develop uterine LMS through malignant transformation of the myometrium,
thus implicating this protein as an anti-tumorigenic candidate as well. In the present study, we
show that LMP2may negatively regulate LMS independently of its role in the proteasome. Moreover,
several lines of evidence indicate that although calponin h1 does not directly inﬂuence tumorigen-
esis, it clearly affects LMP2-induced cellular morphological changes. Modulation of LMP2 may lead
to new therapeutic approaches in human uterine LMS.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Smooth muscle tumors (SMTs) are commonly divided into be-
nign leiomyoma (LMA) and malignant leiomyosarcoma (LMS)
based on cytological atypia, mitotic activity, and other criteria.
Uterine LMS is a rare gynecologic malignancy in the female genital
tract, with an estimated annual incidence of 0.64 per 100,000
women [1]. LMS accounts for approximately one-third of uterine
sarcomas, of which 53% are conﬁned to the uterus [2–5]. Gyneco-
logical tumors are strongly promoted by female hormones. The
rate of hormone receptor expression is reported to be signiﬁcantly
lower in human uterine LMS than in normal myometrium, but
these low receptor levels were found to correlate neither withchemical Societies. Published by E
ology and Infectious Disease,
ano 390-8621, Japan.
shi).the promotion of initial disease development, nor with the overall
survival of patients with uterine LMS.
Although uterine LMS is sensitive to certain types of chemother-
apy with gemcitabine or docetaxel, it is resistant to hormone ther-
apy and radiotherapy, and thus surgical intervention is virtually the
only means of treatment at present [6–8]. It should be noted that
when adjusted for stage and mitotic count, LMS has a signiﬁcantly
worse prognosis than carcinosarcoma; the 5-year survival rate for
patients with uterine LMS is 15–25%. The development of effective
adjuvant treatments is expected to improve the outcome of this dis-
ease through the use of emerging molecular targeting therapies
[4,5,9–11]. Determining the malignant potential of smooth muscle
neoplasms also represents a signiﬁcant diagnostic conundrumwith
important therapeutic ramiﬁcations. However, the genetic changes
underlying the neoplastic transformation of uterine smoothmuscle
cells (SMCs) have not been fully characterized.
The ubiquitin-proteasome degradation pathway is essential for
many cellular processes, including cell cycle and regulation of genelsevier B.V. All rights reserved.
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(LMP)2, LMP7, and LMP10 (MECL-1) subunits is therefore believed
to contribute to the initiation and development of disorders. A re-
cent study revealed a unique role for LMP7 in controlling patho-
genic immune responses and provided a therapeutic rationale for
targeting LMP7 in autoimmune disorders, especially rheumatoid
arthritis [12]. It is also noteworthy that mice with a targeted dis-
ruption of LMP2 exhibited defects in tissue- and substrate-depen-
dent proteasomal function, and that female LMP2-null mice
spontaneously developed uterine LMS with a disease prevalence
of 40% by 14 months of age [13,14]. Furthermore, LMP2 expression
was markedly down-regulated in human uterine LMS tissues in
comparison with both LMA and normal myometrium. This defec-
tive LMP2 expression was attributable to somatic mutations in
the catalytic region of JAK1 in tumor tissues from patients with
uterine LMS [15], and so defective LMP2 expression is likely to
be one of the risk factors in the development of human uterine
LMS as it is in LMP2-null mice [14,15]. In addition, recent reports
have shown an association between malignant transformation of
the myometrium and reduced expression of calponin h1, which
is speciﬁcally expressed in smooth muscle and binds calmodulin,
actin, and tropomyosin [16,17]. Calponin h1 reportedly inhibits
the ATPase activity of myosin and may play a role in smooth mus-
cle contraction [18,19]. Although calponin h1 may function as a tu-
mor-suppressor in uterine LMS, calponin h1-null mice do not
exhibit uterine LMS. The biological characterization of human uter-
ine LMS remains incomplete [16,17].
In the present study, we investigated the molecular mechanism
behind the tumorigenesis of human uterine LMS involving defec-
tive LMP2 expression. Biological and histological ﬁndings showed
that while calponin h1 expression was clearly induced by LMP2,
defective calponin h1 expression contributed to abnormal cell
morphology, but to not cell proliferation, which directly correlated
to tumor progression. Thus, LMP2 expression appeared to be
responsible for the calponin h1-mediated morphological pheno-
types in human uterine LMS cells in an anti-oncogenic manner.
Continued improvement of our knowledge of the molecular biol-
ogy of uterine LMS may ultimately lead to novel diagnoses and
therapies and improved outcome.
2. Materials and methods
2.1. Tissue collection
A total of 51 patients aged between 32 and 83 years who were
diagnosed as having smooth muscle tumors of the uterus were se-
lected from pathological ﬁles. Serial sections were obtained from at
least 2 tissue blocks from each patient for hematoxylin and eosin
staining and immunostaining. All tissues were used with the ap-
proval of the Ethical Committee of Shinshu University after obtain-
ing written consent from each patient.
2.2. Western blotting
To detect the expression of LMP2, LMP7, cyclin B, calponin h1,
SRF, and b-actin, whole cell lysates, nuclear extracts, or cytosolic
extracts were resolved by 10% SDS–PAGE, and immunoblotting
was performed using appropriate antibodies by standard
procedures.
2.3. DNA transfection and isolation of ﬂat revertants
Transfection of pCEM9-LMP2wt, pCEM9-LMPK33A, pCalponin
h1shRNA, pScr.shRNA, or the empty pCEM9 vector was carried
out with FuGENE6 transfection reagent according to the manufac-
turer’s recommendations with 5 lg of plasmid DNA and 5  105SKN cells plated onto 6-well tissue culture dishes on the previous
day.
2.4. Xenograft studies
Nude mice (BALB/cSlc-nu/nu, female, 7–8 weeks old, Japan SLC,
Shizuoka, Japan) were injected intracutaneously with 1  107 cells
of the SKN-CEM9 (T type) clone, SKN-LMP2wt (F type) clone, SKN-
LMP2K33A (F type) clone, SKN-LMP2wt/Scr.shRNA (F type) clone,
or SKN-LMP2wt/calponin h1 shRNA (T type) clone with BD Matri-
gel Matrix (BD Biosciences, MA, USA) in 5 mg/ml of culture med-
ium containing 15% FCS plus SmGM-2 SingleQuots (CAMBREX,
MD, USA) at a volume of 100 ll.
2.5. Reverse transcription-polymerase chain reaction analysis (RT-
PCR) and quantitative RT-PCR
The expression of LMP2, LMP7, calponin h1, SRF, and b-actin
transcripts was examined using RT-PCR. Total RNA was prepared
from human uterine LMS tissues and normal myometrium tissues
with TRIzol reagent according to the manufacturer’s protocol. RNA
was reverse-transcribed with the Superscript II enzyme, and single
stranded cDNAwas used for ampliﬁcation. A LightCycler and SYBR-
Green system were used for quantitative real-time RT-PCR accord-
ing to the manufacturer’s recommendations.
2.6. Immunohistochemistry (IHC)
IHC staining for LMP2, calponin h1, ER, PR, p53, and Ki-67 was
performed on serial human uterine LMS sections. IHC was per-
formed using the avidin–biotin complex method as described
previously.
2.7. Cell transfections and reporter assays
SKN-transfectants, SKN-CEM9#2, SKN-LMP2wt#121, or SKN-
LMP2wt#122 clones were seeded at 70% conﬂuence in 6-well
plates, and a total of 2 lg of luciferase reporter vectors (549cal-
ponin h1 promoter-Luc. or Basic-Luc.) were transfected into SKN-
transfectants with FuGENE6 Transfection Reagent according to
the manufacturer’s recommendations.
Details of methods and any associated references are available
in the Supplementary information3. Results
LMP2 and calponin h1 expression were evaluated using human
tissue samples. IHC revealed a pronounced loss in the ability to in-
duce LMP2 and calponin h1 expression in human uterine LMS tis-
sue in comparison with normal myometrium located in the same
section. Of the 32 patients with uterine LMS examined, 29 were
negative for LMP2, 1 was focally positive, and 1 was partially posi-
tive (Supplementary Fig. 1). One LMS sample retained the expres-
sion of LMP2 (Supplementary Fig. 1). Of the 32 patients with
uterine LMS examined, 31 were negative for calponin h1, and 1
was partially positive (Supplementary Fig. 1). All lymph nodes
were negative for LMS metastases, and IHC showed positivity for
Ki-67 and negativity for LMP2 and calponin h1. In both Western
blotting and RT-PCR experiments, LMP2 and calponin h1 were ex-
pressed in normal myometrium but not in human uterine LMS,
which were strongly supportive of the IHC ﬁndings. Although our
research group previously demonstrated that the abnormal expres-
sion of the ovarian steroid receptors, TP53, and Ki-67, and muta-
tions of TP53 were frequently associated with uterine LMS,
defective LMP2 and calponin h1 expression appeared to be more
1826 T. Hayashi et al. / FEBS Letters 586 (2012) 1824–1831characteristic of uterine LMS in our cohort (Supplementary
Table 1).
The defective LMP2 expression was attributable to somatic
mutations in the catalytic region of JAK1 in tumor tissues from
our patients with uterine LMS [15] (Supplementary Table 1).
Although cell proliferation has been demonstrated to be strongly
inhibited by IFN-c-induced JAK1 kinase activation [20], it is difﬁ-
cult to demonstrate tumorigenicity in JAK1-null mice because they
die perinatally [21]. Therefore, the differential responsiveness to
genetically modiﬁed stable LMP2 expression of the SKN human
uterine LMS cell line was investigated to determine whether rein-
troducing LMP2 into a LMS cell line would affect its tumorigenic
properties for development of uterine LMS and if the observed ef-
fect was due to the immunoproteosomal function of the protein.
SKN cells were transfected with pCEM9, pCEM9-LMP2wt, or
pCEM9-LMP2K33A, which has no effect on immunoproteasome
function due to non-incorporation into the 20S proteasome [22]
(Supplementary Fig. 2), and selected in medium containing G418.
The efﬁciency of neo-marker transfer of these three plasmids was
comparable (Supplementary Table 2). However, in the case of
pCEM9-LMP2wt, approximately 78% (LMP2wt) or 76% (LMP2K33A)
of the total G418-resistant colonies were relatively compact and
appeared dark when observed under a phase-contrast microscopeFig. 1. Biological activity of hLMP2 in uterine leiomyosarcoma (LMS). (A) Phase-contra
revertants of the SKN-LMP2#122 (F type) clone (magniﬁcation 100). Changes in human
(F type) clone xenograft volumes in mice (n = 8). Representative photographs of xenogra
with that of the control transfectant SKN-CEM9 (T type) clone. Tumor growth kinetics a
clone (Right). (B) RT-PCR experiments revealed hLMP2, hLMP7, Calponin h1, SRF, cyclin B
LMP7) and mature LMP2 or LMP7 (LMP2, LMP7) are shown. (C) Western blotting revealed
The luciferase reporter vectors containing the hCalponin h1 promoter with wild type SRF
empty luciferase reporter vector (Basic-Luc.) [23] were transiently co-transfected with
LMP2#122 clones for the ﬁnal 48 h, and then luciferase activities were measured. Valu
expression vector. Each assay was performed at least three times and in triplicate. Lucif
promoter activation. Data are presented as the mean from three independent experim
transformantsa, CEM9 SKN-CEM9#2; LMP2, SKN-LMP2wt#121, SKN-LMP2wt#122. Detai
from the individual xenografted-tumors, which were removed at 5 weeks after xenograafter 6–7 days of selection (Supplementary Table 2). These partially
ﬂat (P/F type) colonies consisted of cells with increased attachment
to the substrate, while the majority of the other transformed (T
type) colonies looked similar in cell morphology to the cells ob-
served in the control dishes, albeit slightly smaller in size (Fig. 1
A, Supplementary Fig. 3). After 2–3 weeks when most of the colo-
nies outgrew and detached from the substrate, colonies consisting
of ﬂatrevertant (F type) cells were found at frequencies of approx-
imately 29.5% (pCEM9-LMP2wt) or 24.8% (pCEM-LMP2K33A) of
the total number of G418-resistant colonies initially observed
(Supplementary Table 2). No colonies of this F type morphology
were observed in the cultures transfected with pCEM9 (Table 1,
Supplementary Fig. 3, Table 2, and 3). We next isolated and ex-
panded representative colonies of each type and analyzed their
growth properties and the occurrence and expression of LMP2.
The growth rate, expressed as doubling time, of typical SKN-
LMP2wt (F type) colonies (8 clones) and SKN- LMP2K33A (F type)
colonies (4 clones) was generally lower than that of SKN-LMP2wt
(P/F type) colonies (2 clones) and control SKN-CEM9 (T type) colo-
nies (4 clones) (Table 1, Supplementary Table 3).
In trials evaluating the anti-tumorigenic properties of LMP2wt
and LMP2K33A, the efﬁciency of colony formation and colony size
in soft agar were greatly reduced in the F type clones and P/F typest micrographs of the parental transformed SKN-CEM9#2 (T type) clone and ﬂat
uterine LMS cell line, SKN-transfectants, SKN-CEM9 (T type) clone, and SKN-LMP2wt
fts in mice (Left). Tumor growth of SKN-LMP2 was markedly reduced in comparison
fter subcutaneous injection of the SKN-CEM9 (T type) clone and SKN-LMP2 (F type)
and b-actin mRNA expression in tumors. Precursor LMP2 or LMP7 (pre-LMP2, pre-
LMP2, LMP7, calponin h1, SRF, cyclin B, and b-actin in SKN-transfectant clones. (D)
binding sites (Calponin-wt-Luc.), mutant SRF binding sites (Calponin-mut-Luc.), or
pSV-b-galactosidase in SKN-transfectants, SKN-CEM9#2, SKN-LMP2#121, or SKN-
es were normalized to those obtained with the co-transfected pSV-b-galactosidase
erase reporter assays showed that LMP2 expression markedly induced calponin h1
ents (⁄S.D.). The experiments were performed four times with similar results. SKN
l is shown in SFig. 2, SFig. 3 and STable 3. RT-PCRb, total RNA samples were isolated
fting. W.B.c, W.B. are performed with the total cell lysates from SKN transformants.
Table 1
Biological/growth properties of transfectants.
Cell lines Morphologye Doubling time (PDT)f SoftAgar Colony Tumori-Genecityi Protein expressionj Inco. LMP2k
Efﬁciency(%)g Sizeh LMP2 LMP7 Calponin Cyclin B
SKN-CEM9a Transformed 15.3 ± 1 60 ± 7 11–27 +++ W L – M –
SKN-LMP2wtb Flatrevertant 17.6 ± 3 5.2 ± 7 5–10 ± H H/M H/M M +
SKN-LMP2K33Ac Flatrevertant 17.2 ± 4 6.1 ± 3 5–11 ± H M M M –
Cryo UtSMCd Flat 19.4 <0.5 – – M M H M +
Details in Table 2 and STable 3.
a Average: SKN-CEM9, total 4 clones.
b Average: SKN-LMP2wt, total 8 clones.
c Average: SKN-LMP2K33A, total 4 clones.
d Cryo UtSMC, Normal Human Uterine Smooth Muscle Cells (CambrexBioScience Walkerville Inc.).
e Morphology. After 2–3 weeks, when most of the colonies outgrew and detached from the substrate, some colonies consisting of very ﬂat cells were found at frequencies of
around a few percent of the total number of G418-resistant colonies initially observed in Table S4. Microscopic characteristics such as ﬂat cell morphology and transformed
cell morphology were analyzed. The number of ﬂat cells or transformed cells in 10 consecutive high-power-ﬁelds was counted. Transformed, no evidence about appearance of
ﬂat cells; Flatrevertant, transformed cell number is less than 10% of total cell number; P.Flat., Partially Flatrevertant, transformed cell number is less than 30% of total cell
number; P.Tras., Partially Transformed, transformed cell number is higher than 30% of total cell number.
f PDT: population doubling time.
g Ratio (%) of soft agar colonies/number of cells plated that have an ability to form colonies on plastic substrate.
h Diameter of colonies as expressed by the number of cells lined up across the colonies; determined on day 21. The experiments were repeated three times with similar
results.
i Cells (1  107) were inoculated subcutaneously into 7–8-weeks old nude mice, and the mice were periodically examined for evidence of tumors, , no evidence of
tumors; +/, tumors of <0.5 cm diameter; +, tumors of 0.5–1.0 cm diameter; ++, tumors of 1.0–1.5 cm diameter, +++, tumors of 1.5–2.0 cm diameter, in two inoculated mice.
Experiments were terminated at 5 weeks after inoculation.
j Estimated by immunoblot analysis. W, weak expression; L, low expression; M, medium expression; H, high expression; –, no evidence of expression.
k Incorporation of LMP2 into proteasome complexes. Proteasome was isolated by GST-UbL beads in accordance with manufacturer’s recomendation (Merck Ltd. Darmstadt,
Germany). Immunoblot analysis was performed. , no evidence of expression; +, Detectable expression of LMP2 by immunoblot analysis.
Table 2
Biological properties of the SKN-transfectants with shRNAs.
Clone no. ora Vector DNAb shRNAc Morphologyd PDT Expressione Tumori-genecityf SoftAgar Colony
LMP2 Calponin Efﬁciency (%)g Sizeh
CEM9#1 Scr Transformed 15.2 – – +++ 58 11–29
CEM9#2 Calpnin Transformed 15.3 – – +++ 67 10–26
CEM9#3 Scr Transformed 15.5 – - ++ 63 11-28
CEM9#4 Calpnin Transformed 15.1 – – ++ 62 11–25
CEM9#5 Scr Transformed 15.3 – – +++ 68 12–24
CEM9#6 Calpnin Transformed 15.5 – – +++ 61 14–26
CEM9#7 Scr Transformed 15.3 – – +++ 64 10–29
CEM9#8 Calpnin Transformed 15.1 – – +++ 59 11–27
bLMP2wt#1 Scr Flatrevertant 17.5 + + ± 5.9 5–10
LMP2wt#2 Calpnin Transformed 17.0 + MD +/+ 6.7 6–12
LMP2wt#3 Scr Flatrevertant 17.6 + + + 5.6 7–11
LMP2wt#4 Calpnin Transformed 16.8 + MD ++ 6.8 6–10
LMP2wt#5 Scr Flatrevertant 17.5 + + ± 6.4 7–14
LMP2wt#6 Calpnin Partially Trans. 16.9 + MD ++ 6.2 5–12
LMP2wt#7 Scr Flatrevertant 17.5 + + + 6.6 6–11
LMP2wt#8 Calpnin Transformed 16.7 + MD ++ 6.9 5–10
a Clone no. Details of SKN transtectant clones are in Table 1 and Table S5.
b Vector DNA. LMP2 expression vector was co-transfected into SKN cells with shRNA vector.
c shRNA, Calponin h1 shRNA or Scramble shRNA were co-transfected into SKN cells with LMP2wt expression vector using manufacturer’s recomendations (Santa Cruz
Biotechnology, Inc., CA, USA).
d Morphology. Microscopic characteristics such as ﬂat cell morphology and transformed cell morphology were analyzed. The number of ﬂat cells or transformed cells in 10
consecutive high-power-ﬁelds was counted. Transformed, no-evidence about appearance of ﬂat cells; Flatrevertant, transformed cell number is less than 10% of total cell
number; P.Flat., Partially Flatrevertant, transformed cell number is less than 30% of total cell number, P.Trans., Partially Transformed, ﬂatrevertant cell number is less than 30%
of total cell number.
e Estimated by immunoblot analysis. +, high expression; , no evidence of expression; MD, marked down-expression.
f Cells (1  107) were inoculated subcutaneously into 7–8-weeks old nude mice, and the mice were periodically examined for evidence of tumors; , no evidence of tumor;
±, tumor of <0.5 cm diameter; +, tumor of 0.5–1.0 cm diameter; ++, tumor of 1.0–1.5 cm diameter; +++, tumor of 1.5–2.0 cm diameter; in two inoculated mice. Experiments
were terminated at 5 weeks after inoculation.
g Ratio (%) of soft agar colonies/number of cells plated that have an ability to form colonies on plastic substrate.
h Diameter of colonies as expressed by the number of cells lined up across the colonies; determined on day 21. The experiments were repeated three times with similar
results.
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type SKN-LMP2wt clones, compared with those in the SKN-CEM9
(T type) clone (Table 1, Supplementary Table 3). Tumor growth
was clearly observed in control mice inoculated with the SKN-
CEM9 (T type) clone, whereas a reduction in tumor growth was ob-served in mice inoculated with the SKN-LMP2wt (F type) or SKN-
LMP2K33A (F type) clones (Fig. 1A, Table 1, Supplementary Ta-
ble 3). Since both wild type and mutant LMP2 blocked tumorigen-
esis, it became necessary to rule out a toxic effect of LMP2
overexpression in a control cancer cell line. Additional experiments
1828 T. Hayashi et al. / FEBS Letters 586 (2012) 1824–1831demonstrated no toxic effects of either wild-type LMP2 or mutant
LMP2K33A overexpression in HeLa cervix cancer cells (data not
shown).
The association between reduced expression of calponin h1 and
malignant transformation of the myometrium suggests that re-Fig. 2. Biological activity of calponin h1 in uterine leiomyosarcoma (LMS). (A) Phase-cont
SKN-CEM9#2 calponin h1shRNA (T type) clone, SKN-CEM9#2 (T type) clone, SKN-LMP2#
SKN-LMP2 (F type) clone (magniﬁcation 60). The growth rates of the SKN-transfectant
RT-PCR experiments revealed calponin h1, precursor LMP2 (pre-LMP2), mature LMP
Scr.shRNA, CEM9#4 Calponin h1shRNA, LMP2#1 Scr.shRNA, LMP2#2 Calponin h1shRNA,
LMS cell line, SKN-transfectant, SKN-CEM9#2 (T type) clone, SKN-LMP2wt#2/Calponin
volumes in mice (n = 3). Representative photographs of xenografts in mice (Left). Tumor
in comparison with that of the SKN-LMP2wt#1/Scr.shRNA (F type) clone. Tumor growth
experiments revealed hCalponin h1, hLMP2 and b-actinmRNA expression in tumors (Botto
CEM9#2; LMP2wt+Calponin h1shRNAd, SKN-LMP2wt#2/ CalponinshRNA; LMP2wt/Scr.sh
SFig. 5 and STable 3. RT-PCRf, total RNA samples were isolated from the individual xe
xenografting. Xenograftsg, BALB/c nu/nu mice were inoculated with SKN-CEM9#2, SKN-expression of human calponin h1 can suppress cell proliferation
and tumorigenicity in uterine LMS cells [16,17]. Calponin h1 was
highly expressed in myometrium and leiomyoma of the uterus,
but was very poorly expressed or negative in LMS [16,17] (Supple-
mentary Fig. 1, Table 1). However, unlike mice lacking LMP2, cal-rast micrographs of the parental transformed SKN-CEM9#1Scr.shRNA (T type) clone,
1Scr.shRNA (F type) clone, and SKN-LMP2#2Calponin h1shRNA (T type) clone of the
clones were measured as population doubling time (PDT). (B) Western blotting and
2 (LMP2), and b-actin in SKN-transfectant clones. SKN transformantsa, CEM9#3
Detail is shown in Table 1 and SFig. 5 and STable 3. (C) Changes in the human uterine
h1shRNA (T type) clone, and SKN-LMP2wt#1/ Scr.shRNA (F type) clone xenograft
growth of the SKN-LMP2wt#2/Calponin h1shRNA (T type) clone is mildly increased
kinetics after subcutaneous injection of the SKN-transfectant clones (Right). RT-PCR
m). Experiments were performed three times with similar results. SKN-CEM9c, SKN-
RNAe, SKN-LMP2wt#1/Scr.shRNA. Details of SKN transfectants are shown in Table 1,
nografted-tumors, which were removed from BALB/c nu/numice at 5 weeks after
LMP2wt#2/CalponinshRNA or SKN-LMP2wt#1/Scr.shRNA.
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the biological connection between LMP2 and calponin h1, we ana-
lyzed the expression pattern of calponin h1 in the SKN-CEM9 clone
(2 clones), SKN-LMP2wt (F type) clone (8 clones), and SKN-
LMP2K33A (F type) clone (4 clones) (Supplementary Fig. 3). Unex-
pectedly, our results revealed that calponin h1 was markedly ex-
pressed in both SKN-LMP2wt (F type) and SKN-LMP2K33A (F
type) clones (Fig. 1B and C, Supplementary Fig. 4, Table 3). Calpo-
nin h1 expression depended on the presence of LMP2, suggesting
that LMP2 may involve the function of calponin h1 in tumor sup-
pression of human uterine LMS. In reporter assays, the calponin
h1 promoter was markedly activated in SKN-LMP2 (F type),
#121, and #122 clones, but not in SKN-CEM9#2, which was
strongly supportive of the RT-PCR and Western blotting assays
(Fig. 1). Recent papers have demonstrated serum response factor
(SRF)-dependent regulation of the human smooth muscle calponin
h1 gene [23,24]. Here, mutation of SRF binding sites abolished the
ability of stable LMP2 expression to induce SRF gene expression in
SKN-LMP2wt (F-type), #121, and #122 clones (Fig. 1D). RT-PCR
and Western blotting experiments showed that stable expression
of LMP2 induced SRF expression, which may account for the activa-
tion of calponin h1 gene expression in SKN-LMP2wt (F-type) clones
(Fig. 1, Supplementary Fig. 4).
To demonstrate the functional signiﬁcance of calponin h1 on
LMP2-induced differential cellular phenotypes, additional experi-
ments were performed on cell morphology, cell cycle, and tumor-
igenesis of human uterine LMS. The SKN cell line was co-
transfected with pCEM9-LMP2wt plus calponin h1shRNA or
Scr.shRNA (negative-control vector) (Santa Cruz Biotechnology
Inc. CA, USA) and then selected in medium containing G418. The
efﬁciency of neo-marker transfer with combinations of these plas-
mids was comparable (Fig. 2). However, in SKN-LMP2/Scr.shRNA
colonies, approximately 96.4% of G418-resistant cells were rela-
tively compact and appeared dark when observed under a phase-
contrast microscope after 6–7 days of selection (Supplementary
Table 4). After 2–3 weeks, when most of the colonies outgrew
and detached from the substrate, colonies consisting of SKN-
LMP2wt/Scr.shRNA ﬂatrevertant (F type) cells (4 clones) were
found at frequencies of approximately 59.1% of the total number
of G418-resistant colonies initially observed (Fig. 2). Furthermore,
colonies of P/T type or T type morphology were observed in cul-
tures co-transfected with LMP2wt plus calponin h1shRNA (4
clones), which speciﬁcally prevents calponin h1 expression
(Fig. 2, Table 2, Supplementary Fig. 5). No colonies with morpho-
logical changes were observed in the SKN cultures co-transfected
with CEM9 plus calponin h1shRNA or Scr.shRNA (Fig. 2, Table 2,
Supplementary Fig. 5). Western blotting and RT-PCR analysis dem-
onstrated that although calponin h1 was clearly detected in the
SKN-LMP2wt/Scr.shRNA colony (4 clones), calponin h1shRNA
markedly prevented calponin h1 expression in the SKN-LMP2wt/
calponin h1shRNA colony (4 clones) (Fig. 2, Table 2, Supplementary
Fig. 4). These ﬁndings suggest that LMP2-induced cellular morpho-
logical phenotypes involved the biological function of calponin h1.
We conﬁrmed that the morphological change was due to the im-
paired expression of calponin h1 by using shRNAs against different
calponin h1 sequences (Supplementary Fig. 6).
We next isolated and expanded representative colonies of each
cell type and analyzed their growth properties. The growth rate of
the SKN-LMP2wt/calponin h1shRNA (T type) colony (4 clones),
measured as population doubling time (PDT), was slightly higher
than that of the SKN-LMP2wt/Scr.shRNA colony (F type) (4 clones)
(Fig. 2, Table 2). We also analyzed their tumorigenic properties as
well as the occurrence and expression of LMP2 and calponin h1.
The efﬁciency of colony formation and size of the clones in soft
agar were not signiﬁcantly reduced in the SKN-LMP2wt/calponin
h1shRNA (T type) colony (4 clones) as compared with those ofthe SKN-LMP2wt/Scr.shRNA (F type) colony (4 clones) (Table 2).
Tumor growth was clearly observed in control mice inoculated
with SKN-CEM9 (T type) (2 clones) (Fig. 1, Supplementary Table 3).
A signiﬁcant reduction in tumor growth was observed in mice
inoculated with the SKN-LMP2wt/Scr.shRNA control (F type) clone
(4 clones); tumors grew slowly in mice inoculated with the SKN-
LMP2wt/calponin h1shRNA (T type) colony (4 clones) in compari-
son with those inoculated with the SKN-CEM9 colony (4 clones)
(Figs. 1 and 2, Tables 1, 2, Supplementary Table 3). The present
experiments suggest that the expression of calponin h1 might af-
fect cell morphology, but not suppression of tumorigenicity in
the LMP2-induced differentiation of cellular phenotype.4. Discussion
Recent molecular targeting therapies against tumors have
achieved remarkable results. To improve the prognosis of human
uterine LMS, studies are being performed to identify the roles of
key pro- and anti-oncogenic factors that have important functions
in tumor pathogenesis and may serve as molecular targets for
treatment. For this purpose, several research groups have shown
that cell cycle regulatory factors and known pro-oncogenic factors,
such as the brain-speciﬁc polypeptide PEP-19 and c-kit, may be
associated with the pathogenesis of human uterine LMS [25–28].
LMP2-null mice are reportedly prone to the spontaneous develop-
ment of uterine LMS [14]. In the present study, histopathological
experiments demonstrated a high correlation between a loss of
LMP2 and calponin h1 and the malignancy of uterine tumors
developing in the myometrium. It is interesting that only LMP2-
null mice spontaneously developed uterine LMS, especially since
the individual expression of LMP2, LMP7, and LMP10/MECL-1 sub-
units has been reported to contribute to the initiation and develop-
ment of several disorders [12,14,15].
Calponin h1 most likely exerts its biologic effects through inter-
actions with other cellular molecules that transduce signals from
outside the cell. Calponin h1 can promote actin ﬁlament stability
in vitro by inhibiting depolymerization [29]. Cell attachment and
spreading are essential for cells to traverse through the G1 phase
of the cell cycle [30]. The present observations on cell morphology
following LMP2-induced calponin h1 expression suggest that cal-
ponin h1 may inhibit the signaling pathways concerned with the
control of cellular morphology, including cell attachment, cell
shape, and spreading. The calponin h1 gene is expressed in resting
aortic SMCs, but its expression rapidly decreases when growth-ar-
rested cells re-enter the G1 phase and proliferate. Thus, this pro-
tein inhibits proliferation in SMCs and ﬁbroblasts [31,32]. Our
ﬁndings show that calponin h1 expression under stable LMP2
expression affects cellular morphology, but does not markedly sup-
press cell proliferation and tumorigenicity in LMS cells.
The molecular mechanisms by which calponin h1 gene-inducing
SRF expression is induced by single-unit LMP2 are poorly under-
stood in LMS. The functionally inactivated K33A mutant of LMP2
has the same morphology in vitro as the wt transfectant, suggest-
ing that LMP2 acts not only through its role in proteasomes, but
also as a single subunit. The relative amounts of LMP2 and LMP7
vary signiﬁcantly among tissues and cell lines in mice and humans
[33], and LMP2 levels in proteasomes show greater variation
among tissues than do those of LMP7 [33]. Proteasome subunits
that are not incorporated into complexes are believed to individu-
ally mediate gene transcriptional activation together with other
co-factors [34]. For instance, LMP2 is also reportedly required for
estrogen receptor-mediated gene transcription as well as for estro-
gen-stimulated cell cycle progression [35]. Other reports have
demonstrated the nuclear localization of single-unit LMP2 in vari-
ous mammalian tissues and cell types [33,36], where single-unit
1830 T. Hayashi et al. / FEBS Letters 586 (2012) 1824–1831LMP2 may regulate calponin h1 gene activation with cellular co-
factors. Further experiments may provide a more complete under-
standing of the tumorigenic phenotypes of SKN cells by non-prote-
osomal LMP2.
LMP2 molecules reportedly associate with cellular factor(s) to
regulate cellular processes, such as cell cycle and gene expression.
The present observations on cell morphology following calponin
h1shRNA expression suggest that single-unit LMP2-mediated cel-
lular factors other than calponin h1 prevent cell proliferation and
tumorigenicity in LMS cells. Elucidation of the mechanism by
which LMP2-induced biological events, including calponin h1
expression, are regulated may provide a great deal of information
about the transformation of cellular phenotypes, the control of cell
proliferative activity, and the pathogenesis of uterine smooth mus-
cle neoplasias at the molecular level. In conclusion, we have shown
that LMP2-induced calponin h1 expression plays a role in the cel-
lular morphological change of LMS cells, and that LMP2 may be a
tumor suppressor in human uterine LMS.
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